Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
P 1 (2)
P 2 (1)

Trial Status

Unknown1
Withdrawn1
Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT06137144Phase 1Recruiting

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

NCT04021082Phase 2Withdrawn

CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)

NCT04423926Phase 1Unknown

Lenalidomide in Combination With CHOP in Patients With Untreated PTCL

Showing all 3 trials

Research Network

Activity Timeline